Advertisement

Treatment for Ligneous Conjunctivitis
Posted: 06/30/2025 | By: Custom Content Team

With the recent FDA approval of plasminogen, human-tvmh (Ryplazim; Kedrion BioPharma), there is now a treatment for plasminogen deficiency type 1, a rare disease in which the most common manifestation is ligneous conjunctivitis. Test your knowledge of the of this systemic disease here.

Question 1 of 5

Although 81% of patients with PLGD-1 present with ligneous conjunctivitis, PLGD-1 is a systemic disease. How many patients had two or more organs affected in the RYPLAZIM clinical trials?

Choose 1

CategoriesView All Quizzes

Retina


Refractive Conditions


Cataract


Cornea


Ocular Surface Disease


Glaucoma


Systemic Disease



Conference Coverage